싱가포르 - 영어 - HSA (Health Sciences Authority)

pioneer medident (se asia) pte. ltd. - cardiovascular - the pta balloon catheter is indicated for percutaneous transluminal angioplasty (pta) in the peripheral vasculature, including iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

싱가포르 - 영어 - HSA (Health Sciences Authority)

pioneer medident (se asia) pte. ltd. - cardiovascular - the peripheral vascular self expanding stent system is intended for primary stenting of de-novo or restenotic lesions of the peripheral arteries.

싱가포르 - 영어 - HSA (Health Sciences Authority)

pioneer medident (se asia) pte. ltd. - cardiovascular - the emax aspiration catheter is indicated for the removal of thrombus and debris in the coronary or peripheral arteries by percutaneous suction.

싱가포르 - 영어 - HSA (Health Sciences Authority)

alcare pharmaceuticals pte ltd - cardiovascular - the pta balloon catheter is indicated for percutaneous transluminal angioplasty (pta) in the peripheral vasculature, including femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

싱가포르 - 영어 - HSA (Health Sciences Authority)

alcare pharmaceuticals pte ltd - cardiovascular - the guiding sheath (gsq) is intended to introduce therapeutic or diagnostic devices into the vasculature, excluding coronary, central circulatory system and neuro vasculature.

싱가포르 - 영어 - HSA (Health Sciences Authority)

alcare pharmaceuticals pte ltd - cardiovascular - support catheter (scq) is intended to facilitate the introduction of guidewire into peripheral vascular system for interventional procedures.

미국 - 영어 - NLM (National Library of Medicine)

qualitest pharmaceuticals - clonazepam (unii: 5pe9fde8gb) (clonazepam - unii:5pe9fde8gb) - clonazepam 0.5 mg - clonazepam is useful alone or as an adjunct in the treatment of the lennox-gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. in patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. in some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. in some cases, dosage adjustment may re-establish efficacy. clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in dsm-v. panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. the efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the dsm-iiir category of panic disorder (see clinical pharmacology :  clinica

캐나다 - 영어 - Health Canada

monarch pharmaceuticals ireland limited - quinupristin; dalfopristin - powder for solution - 150mg; 350mg - quinupristin 150mg; dalfopristin 350mg - streptogramins

캐나다 - 영어 - Health Canada

jubilant hollisterstier llc - white faced hornet venom protein - powder for solution - 1300mcg - white faced hornet venom protein 1300mcg - allergenic extracts

미국 - 영어 - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride tablets are indicated for the treatment of major depressive disorder. the efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effic